GlassScriptPhysician profile
David S Batt
NPI 1972547529
$577,109.78
in general payments reported to CMS, 2019-2025
18 companies · $71K in 2025
The $71K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $71K · 2021: $51K · 2022: $87K · 2023: $78K · 2024: $64K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $185K · Travel and Lodging: $13K · Food and Beverage: $9,429 · Consulting Fee: $4,415 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $184,822.50 |
| Travel and Lodging | $13,478.48 |
| Food and Beverage | $9,428.54 |
| Consulting Fee | $4,415.00 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $126,497.54 | 2019-2025 | Benlysta |
| Mallinckrodt Enterprises LLC | $98,057.92 | 2019 | |
| Mallinckrodt Hospital Products INC. | $93,739.48 | 2020-2025 | Acthar |
| Amgen INC. | $79,440.33 | 2020-2025 | Uplizna, Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56,657.02 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $39,391.22 | 2022-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $30,786.66 | 2021-2024 | Lupkynis |
| Abbvie INC. | $30,001.61 | 2019-2025 | Rinvoq |
| Horizon Therapeutics Plc | $20,614.46 | 2019-2023 | Krystexxa |
| Ucb, INC. | $682.13 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $282.52 | 2019-2025 | Orencia, Sotyktu |
| Celgene Corporation | $233.21 | 2019 | |
| Janssen Biotech, INC. | $228.20 | 2024-2025 | Tremfya, Simponi Aria |
| Cardinal Health 110 LLC | $200.00 | 2021-2022 | |
| Pfizer INC. | $99.62 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.91 | 2025 | Zepbound, Taltz |
| Boston Scientific Corporation | $62.24 | 2023-2025 | General - Therapies |
| Novartis Pharmaceuticals Corporation | $44.71 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Batt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.